https://www.regulatoryrapporteur.org/chemistry-manufacturing-and-controls/empowering-digital-innovation-in-cmc-a-framework-for-regulatory-readiness-and-confidence/1033.article 2026-01-14T09:44:39.053Z https://www.regulatoryrapporteur.org/demystifying-complex-generic-products-regulatory-pathways-and-characterisation/1034.article 2026-01-14T09:52:42.063Z https://www.regulatoryrapporteur.org/medical-devices/2025-uk-mdr-regulatory-conference-meeting-report/1035.article 2026-02-06T09:17:20.730Z https://www.regulatoryrapporteur.org/medical-devices/overview-of-the-regulatory-and-development-landscape-for-brain-computer-interfaces-in-neurodegenerative-disease-treatment/1037.article 2026-01-14T10:23:57.970Z https://www.regulatoryrapporteur.org/pharmaceuticals/regulatory-challenges-and-key-considerations-in-the-development-of-radiopharmaceuticals/1038.article 2026-01-14T11:47:00.230Z https://www.regulatoryrapporteur.org/artificial-intelligence/the-evolving-role-of-the-regulatory-professional-in-the-age-of-artificial-intelligence/1039.article 2026-01-14T09:45:40.190Z https://www.regulatoryrapporteur.org/editorials/navigating-complexity-regulation-at-the-interface-of-innovation-technology-and-confidence/1040.article 2026-02-05T15:20:50.933Z https://www.regulatoryrapporteur.org/podcasts/regrappod--inconversation-with-parexel/1044.article 2026-04-10T10:55:52.287Z https://www.regulatoryrapporteur.org/industry-news/fda-and-ema-publish-guiding-principles-of-good-ai-practice-in-drug-development/1046.article 2026-01-27T11:42:51.327Z https://www.regulatoryrapporteur.org/industry-news/mhra-invites-call-for-evidence-to-assess-ai-regulation/1047.article 2026-01-28T11:21:57.063Z https://www.regulatoryrapporteur.org/industry-news/mhra-points-to-clinical-trial-growth-and-faster-assessment-routes/1048.article 2026-02-18T12:30:18.750Z https://www.regulatoryrapporteur.org/in-vitro-diagnostics/navigating-regulatory-scrutiny-an-analysis-of-requests-for-information-in-eu-combined-clinical-trials/1049.article 2026-02-06T09:20:55.827Z https://www.regulatoryrapporteur.org/medical-devices/reckoning-with-risk-navigating-medtech-innovation/1050.article 2026-02-06T09:20:29.063Z https://www.regulatoryrapporteur.org/industry-news/din-spec-91509-a-milestone-for-structured-digital-medical-device-documentation/1051.article 2026-03-23T08:46:43.310Z https://www.regulatoryrapporteur.org/medical-devices/from-design-to-diversity-embedding-womens-health-into-medical-device-innovation-and-regulation/1052.article 2026-02-06T09:22:24.900Z https://www.regulatoryrapporteur.org/medical-devices/wearable-technology-the-fine-regulatory-line-between-health-and-wellness/1053.article 2026-02-06T09:21:42.843Z https://www.regulatoryrapporteur.org/combination-products/parenteral-drug-delivery-systems-driving-clinical-success/1054.article 2026-03-06T15:11:23.510Z https://www.regulatoryrapporteur.org/editorials/medtech-in-transition-regulation-risk-and-real-world-impact/1055.article 2026-02-06T08:43:54.387Z https://www.regulatoryrapporteur.org/industry-news/fda-approves-non-invasive-device-for-pancreatic-cancer-treatment/1059.article 2026-02-13T16:22:54.387Z https://www.regulatoryrapporteur.org/industry-news/new-ich-m15-guideline-sets-harmonised-framework-for-midd/1060.article 2026-02-18T11:40:56.853Z https://www.regulatoryrapporteur.org/industry-news/mhra-seeks-views-on-indefinite-acceptance-of-ce-marked-medical-devices/1062.article 2026-03-23T08:46:37.223Z https://www.regulatoryrapporteur.org/industry-news/fda-launches-framework-for-accelerating-development-of-individualised-therapies-for-ultra-rare-diseases/1063.article 2026-02-26T15:47:27.263Z https://www.regulatoryrapporteur.org/biologics/navigating-regulatory-pathways-for-live-biotherapeutics-in-the-us-and-eu-challenges-and-opportunities/1064.article 2026-03-06T15:18:43.057Z https://www.regulatoryrapporteur.org/atmp/cell-therapy-gene-therapy-and-tissue-engineered-product-manufacturing-technical-challenges-enablers-and-regulatory-evolution/1065.article 2026-04-08T14:20:16.333Z https://www.regulatoryrapporteur.org/atmp/navigating-advanced-therapy-medicinal-product-regulatory-changes-european-medicines-agency-and-uk-guidance-updates/1066.article 2026-03-06T15:17:32.657Z https://www.regulatoryrapporteur.org/wma-declarations-helsinki-in-the-spotlight-and-taipei-in-the-background/1067.article 2026-03-06T15:16:37.667Z https://www.regulatoryrapporteur.org/biologics/beyond-product-approval-bridging-the-gap-between-regulatory-success-and-patient-access-for-biosimilars/1068.article 2026-03-06T15:16:09.170Z https://www.regulatoryrapporteur.org/pharmaceuticals/the-eus-health-technology-assessment-regulation-implementation-one-year-on/1069.article 2026-04-10T11:05:37.590Z https://www.regulatoryrapporteur.org/artificial-intelligence/topra-annual-lecture-2026-the-global-imperative-for-responsible-ai-in-healthcare/1070.article 2026-03-06T15:13:41.680Z https://www.regulatoryrapporteur.org/editorials/the-innovation-era-where-biology-meets-technology/1071.article 2026-04-10T17:12:49.733Z https://www.regulatoryrapporteur.org/thought-leadership/the-future-of-regulatory-affairs-from-siloed-structures-to-data-driven-healthcare-innovation/1074.article 2026-03-25T09:06:42.970Z https://www.regulatoryrapporteur.org/industry-news/fda-launches-new-consolidated-adverse-event-reporting-system/1075.article 2026-03-23T09:14:08.613Z https://www.regulatoryrapporteur.org/industry-news/act-eu-issues-draft-guidance-on-clinical-trials-during-emergencies/1076.article 2026-04-07T08:57:48.790Z https://www.regulatoryrapporteur.org/industry-news/fda-advances-commitment-to-moving-beyond-animal-testing/1077.article 2026-04-07T09:17:04.153Z https://www.regulatoryrapporteur.org/product-information/the-regulatory-valuation-of-patient-experience-data-in-rare-diseases-a-review-of-fda-and-ema-labelling-outcomes-and-methodological-determinants/1078.article 2026-04-13T10:13:08.220Z https://www.regulatoryrapporteur.org/podcasts/regrappod--inconversation-with-magda-papadaki/1079.article 2026-04-08T11:44:00.050Z https://www.regulatoryrapporteur.org/clinical-trials/plain-language-results-in-uk-clinical-trials-navigating-new-regulatory-requirements-and-practical-challenges/1081.article 2026-04-13T10:13:23.857Z https://www.regulatoryrapporteur.org/pharmaceuticals/beyond-borders-strengthening-regional-regulatory-frameworks-to-end-substandard-and-falsified-medicines-in-africa/1082.article 2026-04-13T10:13:53.723Z https://www.regulatoryrapporteur.org/regulatory-procedures/the-strategic-role-of-regulatory-operations-in-digital-transformation-success/1083.article 2026-04-13T10:14:09.533Z https://www.regulatoryrapporteur.org/in-vitro-diagnostics/emergency-use-authorisation-of-in-vitro-diagnostic-devices-by-the-us-fda-the-regulatory-framework-lessons-from-covid-19-and-future-directions/1084.article 2026-04-13T10:12:49.970Z https://www.regulatoryrapporteur.org/regulatory-procedures/regulatory-affairs-as-a-strategic-function-in-market-access-of-medicinal-products-precovid-19-context-covid-19-acceleration-and-postcovid-19-convergence-across-11-markets/1085.article 2026-04-13T10:12:35.337Z https://www.regulatoryrapporteur.org/medical-devices/lean-six-sigma-in-post-market-surveillance-insights-for-eu-2017/745-mdr-article-88-and-great-britain-si-2024/1368-44zn-trend-reporting-compliance/1086.article 2026-04-14T11:57:07.410Z https://www.regulatoryrapporteur.org/editorials/access-to-medicines-from-approval-to-patient-centred-delivery/1087.article 2026-04-13T10:46:06.497Z